Soroceanu Lab

California Pacific CURRENTS: The online journal of CPMC Research Institute

Glioblastoma tissue
Human cytomegalovirus co-localizes with stemness markers in fresh glioblastoma markers in situ.
Overview

Each year in the U.S., 15,000 people are diagnosed with brain cancer. Even with standard-of-care radiation therapy, most patients have an expected survival of approximately 15 months after diagnosis. The most intractable form of brain cancer, glioblastoma multiforme is an aggressive brain tumor that is fatal in almost all cases.

Our lab is studying the development and progression of glioblastomas, and developing novel therapies to improve patients’ prognosis.

Part of our research is aimed at understanding the role of human cytomegalovirus (HCMV, a common herpes virus) in the growth of tumors. We are also investigating the ability of non-psychoactive cannabinoid compounds such as cannabidiol (CBD) to sensitize glioblastomas to frontline radiation and chemotherapy.

Lead Investigator
Lab Members
Neetha Eduthan, MS
Volunteer
Alyssia Oh, B.Sc.
Research Associate
Eric Singer, B.Sc.
Research Associate
Lynn Wang, MS
Research Associate

 

Current Projects
  • CPMCRI's Cancer Avatar Project
  • Role of cytomegalovirus in the development of malignant gliomas
  • Anti-viral therapy for glioblastoma
  • Cannabinoids as antineoplastic agents
  • The biology of glioma stem cells
  • Targeting therapeutic resistance in glioma using non-toxic ROS modulators